ArticleScientific reports2025
Prognostic value assessment and in vitro validation of mitochondria-ferroptosis-related genes in multiple myeloma.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Multiple myeloma (MM) is a malignant plasma cell tumor. Mitochondria-related genes (MRGs) are significant inducers of ferroptosis. However, research on the involvement of mitochondria-ferroptosis-related genes (MFRGs) in the MM is relatively scarce, and further identification of key genes associated with MFRGs in MM treatment is needed. In this study, transcriptomic data and related genes were initially downloaded from public databases and literature. Subsequently, candidate genes were obtained by intersecting the differential expression genes (DEGs) from MM and control groups, and MFRGs. Through regression analyses, clinically relevant genomic signatures were delineated, culminating in the development of a predictive algorithm. An independent prognostic analysis was conducted, followed by the creation of a nomogram. Subsequently, these prognostic genes were studied from various aspects. Finally, the transcriptional abundance of predictive biomarkers was experimentally validated through reverse transcription quantitative polymerase chain reaction (RT-qPCR). The intersection of DEGs and MFRGs yielded 15 candidate genes. Then, GPR15, NLRP7, ZNF208, PRDM13, and CRIM1 were identified as prognostic genes. The prognostic model constructed using these prognostic genes was confirmed to be robust. The 2 independent prognostic factors (risk score and age) were determined, and the constructed nomogram provided an excellent predictive model. Then, risk score and activated dendritic cells were found to be significantly negatively correlated (cor = -0.43, p < 0.05). Additionally, GPR15 was positively associated with M2 macrophages (cor = 0.34, p < 0.05), while NLRP7 and PRDM13 were negatively associated with activated dendritic cells (cor = -0.34, p < 0.05; cor = -0.40, p < 0.05). There were 3 significantly different immune cells, 31 significantly immune checkpoint genes, and 11 significantly different immune checkpoints (p < 0.05). ZNF208, PRDM13, and CPIM1 were all mainly enriched in ribosome-related pathways. Finally, 86 potential drugs for the treatment of MM were discovered, such as shikonin. RT-qPCR results showed that NLRP7 and PRDM13 were significantly upregulated in MM group, while GPR15 and CRIM1 were significantly downregulated in MM group (p < 0.05). In this study, 5 MFRGs were identified as prognostic genes (GPR15, NLRP7, ZNF208, PRDM13, and CRIM1) for MM, which provide reference significance for the prognosis of MM.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.